Joel R. Lexchin

121 Walmer Rd, M5R 2X8
Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 255 publications

Artificial intelligence as a new commercial determinant of health.

Artificial intelligence as a new commercial determinant of health.

Journal: BMJ (Clinical research ed.)

Published: July 21, 2026

The World Expected More of Canada: Canada and the Pandemic Agreement.

The World Expected More of Canada: Canada and the Pandemic Agreement.

Journal: International journal of social determinants of health and health services

Published: June 18, 2026

Implications of relying on manufacturer patient support programs for access to high-cost specialty and biologic medicines: a critical qualitative study.

Implications of relying on manufacturer patient support programs for access to high-cost specialty and biologic medicines: a critical qualitative study.

Journal: BMJ open

Published: June 08, 2026

Joint working between the NHS and pharma-do the claims add up?

Joint working between the NHS and pharma-do the claims add up?

Journal: Drug and therapeutics bulletin

Published: April 02, 2026

Doctors' Conflict-of-Interest; What it Looks Like and What to do About it.

Doctors' Conflict-of-Interest; What it Looks Like and What to do About it.

Journal: International journal of social determinants of health and health services

Published: March 19, 2026

Are gaps in the time of submissions and approvals of new drugs between Health Canada and the Food and Drug Administration related to therapeutic value? A cross-sectional study.

Are gaps in the time of submissions and approvals of new drugs between Health Canada and the Food and Drug Administration related to therapeutic value? A cross-sectional study.

Journal: Health policy (Amsterdam, Netherlands)

Published: February 23, 2026

Comparison in the Use of Regulatory Pathways Between Health Canada and the Food and Drug Administration: A Cross-sectional Study.

Comparison in the Use of Regulatory Pathways Between Health Canada and the Food and Drug Administration: A Cross-sectional Study.

Journal: Journal of general internal medicine

Published: January 14, 2026

Risk management plans and drug safety in Canada: A cross-sectional study.

Risk management plans and drug safety in Canada: A cross-sectional study.

Journal: The International journal of risk & safety in medicine

Published: December 28, 2025

Evaluating conflict-of-interest governance among Canadian medical societies using a novel assessment tool: A cross-sectional study.

Evaluating conflict-of-interest governance among Canadian medical societies using a novel assessment tool: A cross-sectional study.

Journal: PloS one

Published: November 29, 2025

An opportunity to remove harmful intellectual property provisions from the Comprehensive and Progressive Agreement for Trans-Pacific Partnership.

An opportunity to remove harmful intellectual property provisions from the Comprehensive and Progressive Agreement for Trans-Pacific Partnership.

Journal: Health economics, policy, and law

Published: November 26, 2025

Addressing the challenge of post-approval regulation of pharmaceuticals: The case for independent third-party evaluations.

Addressing the challenge of post-approval regulation of pharmaceuticals: The case for independent third-party evaluations.

Journal: Health policy (Amsterdam, Netherlands)

Published: October 11, 2025

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta-analysis.

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta-analysis.

Journal: British journal of clinical pharmacology

Published: October 01, 2025

Showing 1-12 of 255

Last Updated: 09/26/2026